Treatment of autism spectrum disorders: Neurotransmitter signaling pathways involved in motivation and reward as therapeutic targets

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 8, 2008, Pages 949-967

  Walker, Michael A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

aminobutyric acid; Acetylcholine; Asperger; Dopamine; Nicotinic acid; Oxytocin; Rett; Vasopressin

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; 4 AMINOBUTYRIC ACID RECEPTOR; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ACR 16; AMANTADINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CARBETOCIN; CLONAZEPAM; DEXTROMETHORPHAN; DIANICLINE; DOPAMINE; DOPAMINE RECEPTOR AFFECTING AGENT; FLUMAZENIL; GANAXOLONE; LAMOTRIGINE; NICOTINIC AGENT; NITRAZEPAM; OXYTOCIN; PLACEBO; RISPERIDONE; SSR 591813; TC 2403; TETRAHYDROBIOPTERIN; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VASOPRESSIN; VIGABATRIN;

ASPERGER SYNDROME; AUTISM; BLOOD PRESSURE; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINERGIC ACTIVITY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENVIRONMENTAL FACTOR; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; GENE CLUSTER; GENE LOCATION; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HEART RATE; HORMONE ACTION; HUMAN; INCIDENCE; LIGAND BINDING; NEUROPATHOLOGY; NEUROTRANSMITTER RELEASE; NONHUMAN; OXYTOCIN RELEASE; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL BEHAVIOR; TRANQUILIZING ACTIVITY; VASOPRESSIN RELEASE;

ANIMALS; AUTISTIC DISORDER; HUMANS; MOTIVATION; NEUROTRANSMITTER AGENTS; REWARD; SIGNAL TRANSDUCTION;

EID: 48449088655     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.8.949     Document Type: Review

References (133)

1. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. american psychiatric associate; Washington, DC; 1994
2. International classification of diseases. 10th edition, world health organization, Geneva Switzerland; 1992
3. Ganz ML. The lifetime distribution of the incremental societal costs of autism. Arch Pediatr Adolesc Med 2007;161:343-349
4. Autism Prevalence in the US. Rises to 1 in 150; 2007. Available from: www.autism-soctety.org/site/News2?page=NewsArticle&id=9289 [Last accessed 12 May 2008]
5. Thornton-Wells TA, Moore JH, Haines JL. Genetics, statistics and human disease: analytical retooling for complexity. Trends Genet 2004;20(12):640-7
6. Veenstra-Vanderweele J, Christian SL, Cook EH Jr. Autism as a paradigmatic complex genetic disorder. Ann Rev Genomics Hum Genet 2004;5:379-405
7. Grant SGN. Systems biology in neuroscience: bridging genes to cognition. Current Opin Neurobiol 2003;13:577-82
8. Baron-Cohen S, Ring HA, Bullmore ET, et al. The amygdala theory of autism. Neurosci Biobehav Rev 2000;24(3):355-64
9. Insel TR. Is social attachment an addictive disorder? Physiol Behav 2003;79(3):351-7
10. Kovacs GL, Sarnyai Z, Szabo G. Oxytocin and addiction: a review. Psychoneuroendocrinology 1998;23(8):945-62
11. Hammock EAD, Young LJ. Oxytocin, vasopressin and pair bonding: implications for autism. Philosoph Trans Royal Soc B Biol Sci 2006;361(1476):2187-98
12. Lim MM, Young LJ. Neuropeptidergic regulation of affiliative behavior and social bonding in animals. Hormones Behav 2006;50(4):506-17
13. Young LJ, Wang Z. The neurobiology of pair bonding. Nature Neurosci 2004;7(10):1048-54
14. Winslow JT, Hastings N, Carter CS, et al. A role for central vasopressin in pair bonding in monogamous prairie voles. Nature 1993;365(6446):545-8
15. Le Moal M, Dantzer R, Michaud B, Koob GF. Centrally injected arginine vasopressin (AVP) facilitates social memory in rats. Neurosci Lett 1987;77(3):353-9
16. Landgraf R, Gerstberger R, Montkowski A, et al. V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J Neurosci 1995;15(6):4250-8
17. Everts HGJ, Koolhaas JM. Lateral septal vasopressin in rats: role in social and object recognition? Brain Res 1997;760(1-2):1-7
18. Levy F, Kendrick KM, Goode JA, et al. Oxytocin and vasopressin release in the olfactory bulb of parturient ewes: changes with maternal experience and effects on acetylcholine, γ-aminobutyric acid, glutamate and noradrenaline release. Brain Res 1995;669(2):197-206
19. Ferguson JN, Aldag J, Matthew I, et al. Oxytocin in the medial amygdala is essential for social recognition in the mouse. 2001;21(20):8278-85
20. Takayanagi Y, Yoshida M, Bielsky IF, et al. Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice. 2005;102(44):16096-101
21. Bielsky IF, Hu S-B, Re X, et al. The V1a vasopressin receptor is necessary and sufficient for normal social recognition: a gene replacement study. Neuron 2005;47(4):503-13
22. Bielsky IF, Young LJ. Oxytocin, vasopressin, and social recognition in mammals. Peptides 2004;25(9)1565-74
23. Jin D, Liu H-X, Hirai H, et al. CD38 is critical for social behaviour by regulating oxytocin secretion. Nature 2007;446(7131):41-5
24. Modahl C, Green LA, Fein D, et al. Plasma oxytocin levels in autistic children. Biol Psychiatry 1998;43(4):270-7
25. Green L-A, Fein D, Modahl C, et al. Oxytocin and autistic disorder: alterations in peptide forms. Biol Psychiatry 2001;50(8):609-13
26. Wu S, Jia M, Ruan Y, et al. Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han population. Biol Psychiatry 2005;58(1):74-7
27. Inoue T, Kimura T, Azuma C, et al. Structural organization of the human oxytocin receptor gene. J Biol Chem 1994;269(51):32451-6
28. Baron-Cohen S, Wheelwright S, Hill J, et al. The "reading the mind in the eyes" test, revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry Allied Discp 2001;42(2):241-51
29. Domes G, Heinrichs M, Michel A, et al. Oxytocin improves "mind reading" in humans. Biol Psychiatry 2007;61(6):731-3
30. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature 2005;435(7042):673-6
31. Zak, PJ, Kurzban R, Matzner WT. Oxytocin is associated with human trustworthiness. Horm Behav 2005;48(5):522-7
32. Stein MB, Goldin PR, Sareen J, et al. Increased amygdala activation to angry and contemptuous faces in generalized social phobias. Arch Gen Psychiatry 59(11):1027-34
33. Kirsch P, Esslinger C, Chen Q, et al. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 2005;25(49):11489-93
34. Meyer-Lindenberg A, Hariri AR, Munoz KE, et al. Neural correlates of genetically abnormal social cognition in Williams syndrome. Nat Neurosci 2005;8(8):991-3
35. Hollander E, Novotny S, Hanratty M, et al. Oxytocin infusion reduces repetitive behaviours in adults with autistic and Asperger disorder. Neuropsychopharmacol 2003;28(1):193-8
36. Hollander E, Bartz J, Chaplin W, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry 2006;61(4):498-503
37. Kim S-J, Young LJ, Gonen d, et al. Transmission disequilibrium testing of arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism. Mol Psychiatry 2002;7(5):503-7
38. Wassink TH, Piven J, Vieland VJ, et al. Examination of AVPR1a as an autism susceptibility gene. Mol Psychaitr 2004;9(10):968-72
39. Yirmiya N, Rosenberg, C, Levi S, et al. Association between the arginine vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: mediation by socialization skills. Mol Psychiatry 2006;11(5):488-94
40. Ring RH, Malberg JE, Potestio L, et al. Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology 2006;185(2):218-25
41. De Groot AN, Vree TB, Hekster YA, et al. Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. J Pharm Pharmacol 1995;47(7):571-5
42. Meraldi JP, Hruby VJ, Brewster AI. Relative conformational rigidity in oxytocin and [1-penicillamine]-oxytocin: a proposal for the relationship of conformational flexibility to peptide hormone agonism and antagonism. Proc Natl Acad Sci USA 1977;74(4):1373-7
43. Yuan Z-Q, Blomberg D, Sethson I, et al. Synthesis and pharmacological evaluation of an analogue of the peptide hormone oxytocin that contains a mimetic of an inverse γ-turn. J Med Chem 2002;45(12):2512-9
44. Hruby VJ, Chow MS, Smith DD. Conformational and structural considerations in oxytocin-receptor binding and biological activity. Ann Rev Pharmacol Toxicol 1990;30:501-34
45. Wittelsberger A, Patiny L, Slaninova J, et al. Introduction of a cis-prolyl mimic in position 7 of the peptide hormone oxytocin does not result in antagonistic activity. J Med Chem 2005;48(21):6553-62
46. Hruby VJ. Designing peptide receptor agonists and antagonists. Nat Rev Drug Disc 2002;1(11):847-58
47. Engstrøm T, Barth T, Melin P, Vilhardt H. Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Eur J Pharmacol 1998;355(2-3):203-10
48. Stymiest JL, Mitchell BF, Wong S, Vederas JC. Synthesis of biologically active dicarba analogues of the peptide hormone oxytocin using ring-closing metathesis. Org Lett 2003;5(1):47-9
49. Keller O, Rudiger J. Synthesis of (1,6-α,α′-disminosuberic acid) oxytocin (dicarba-oxytocin). Helv Chim Acta 1974;57(5):1253-9
50. Walter R, Yamanaka T, Sakakibara S. Neurohypophyseal hormone analog with selective oxytocin-like activities and resistance to enzymatic inactivation. Approach to the design of peptide drugs. Proc Natl Acad Sci USA 1974;71(5):1901-5
51. Evans BE, Leighton JL, Rittle KE, et al. Orally active, nonpeptide oxytocin antagonists. J Med Chem 1992;35(21):3919-27
52. Bell IM, Erb JM, Freidenger RM, et al. Development of orally active oxytocin antagonists, Studies on 1-(1-[4-[20methyl-1-oxidopyridin-3- ylmethyl]piperidin-4-yloxy}-2-methoxybenzoly) piperidin-4-yl)-1,4- dihydrobenz[d] [1,3]oxazin-2-one (L-372,662) and related pyridines. J Med Chem 1998;41(12):2146-63
53. Pitt RW, Batt AR, Haigh RM, et al. Non-peptide oxytocin agonists. Bioorg Med Chem Lett 2004;14(17):4585-9
54. Ashworth DM, Batt AR, Baxter AJ, et al. Nonpeptide oxytocin agonists. Drugs Future 2006;31(4):345-53
55. Schroer RJ, Phelan MC, Michaelis RC, et al. Autism and maternally derived aberrations of chromosome 15q. Am J Med Genet 1998;76(4):327-36
56. Blatt GJ. GABAergic cerebellar system in autism: a neuropathological and developmental perspective. Int Rev Neurobiol 2005;71:167-78
57. Rivto ER, Freeman BJ, Scheibel AB, et al. Lower Purkinje cell counts in the cerebella of four autistic subjects: initial findings of the UCLA-NSCA autopsy research report. Am J Psychiatry 1986;143(7):862-6
58. Mccauley JL, Olson LM, Delahanty R, et al. A linkage disequilibrium map of the 1-Mb 15q12 GABAA receptor subunit cluster and association to autism. Am J Med Genet Part B Neuropsych Genetics 2004;131(1):51-9
59. Bass MP, Menold MM, Wolpert M, et al. Genetic studies in autistic disorder and chromosome 15. Neurogenetics 2000;2(4):219-26
60. Chagnon YC. Shared chromosomal susceptibility regions between autism and other mental disorders. Int Rev Neurobiol 2005;71:419-43
61. Takayama C. GABAergic signalling in the developing cerebellum. Int Rev Neurobiol 2005;71:63-94
62. Ben-Ari Y. Excitatory actions of GABA during development: the nature of the nurture. Nature Rev Neurosci 2002;3(9):728-39
63. Laviolette SR, Gallegos RA, Henriksen SJ, Van Der Kooy D. Opiate state controls bi-directional reward signalling via GABAA receptors in the ventral tegmental area. Nature Neurosci 2004;7(2):160-9
64. Ikemoto S. The supramammillary nucleus mediates primary reinforcement via GABAA receptors. Neuropsychopharmacology 2005;30:1088-95
65. Johnson BA. Recent advances in the development of treatments for alcohol and cocaine dependence. CNS Drugs 2005;19(10):873-96
66. Solis-Anez E, Delgado-Luengo W, Borjas-Fuentes L, et al. Molecular analysis of the GABRB3 gene in autistic patients: an exploratory study. Invest Clin 2007;48(2):225-42
67. Cook EH Jr, Courchesne RY, Cox NJ, et al. Linkage-disequilibrium mapping of autistic disorder, with 15q11-13 markers. Am J Hum Genet 1998;62(5):1077-83
68. Buxbaum JD, Silverman JM, Smith CJ, et al. Association between a GABRB3 polymorphism and autism. Mol Psychiatry 2002;7(3):311-6
69. Menold MM, Shao Y, Wolpert CM, et al. Association analysis of chromosome 15 GABAA receptor subunit genes in autistic disorder. J Neurogenet 2001;15(3-4):245-59
70. Shao Y, Cuccaro ML, Hauser ER, et al. Fine mapping of autistic disorder to chromosome 15q11-q13 by use of phenotypic subtypes. Am J Hum Genet 2003;72(3):539-48
71. Guptill JT, Booker AB, Gibbs TT, et al. [3H]-Flunitrazepam-labeled benzodiazepine binding sites in the hippocampal formation in autism: a multiple concentration autoradiographic study. J Autism Dev Disord 2007;37(5):911-20
72. Curran S, Powell J, Neale BM, et al. An association analysis of candidate genes on chromosome 15 q11-13 and autism spectrum disorder. Mol Psychiatry 2006;11(8):709-13
73. Fatemi SH, Halt AR, Stary JM, et al. Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry 2002;52(8):805-10
74. Yip J, Soghomonian J-J, Blatt GJ. Decreased GAD67 mRNA levels in cerebellar Purkinje cells in autism: pathological implications. Acta Neuropathol 2007;113(5):559-68
75. Moreno-Fuenmayor H, Borjas L, Arrieta A, et al. Plasma excitatory amino acids in autism. Invest Clin 1996;37(2):113-28
76. Aldred S, Moore KM, Fitzgerald M, Waring RH. Plasma amino acid levels in children with autism and their families. J Autism Dev Disord 2003;33(1):93-7
77. Shinohe A, Hashimoto K, Nakamura K, et al. Increased levels of glutamate in adult patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1472-7
78. Page LA, Daly E, Schmitz N, et al. In vivo 1H-magnetic resonance spectroscopy study of amygdala-hippocampal and parietal regions in autism. Am J Psychiatry 2006;163:2189-92
79. Coulter DA. Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in? J Child Neurol 1997;12(Suppl 1):S2-9
80. Belsito KM, Law PA, Kirk KS, et al. Lamotrigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2001;32(2):175-81
81. King BH, Wright DM, Handen BL, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2001;40(6):658-65
82. Woodward C, Groden J, Goodwin M, Bodfish J. A placebo double-blind pilot study of dextromethorphan for problematic behaviours in children with autism. Autism 2007;11(1):29-41
83. Schmitz C, Van Kooten IA, Hof PR, et al. Steinbusch HW, Autism: neuropathology, alterations of the GABAergic system, and animal models. Int Rev Neurobiol 2005;71:1-26
84. Delorey TM, Sahbaie P, Hashemi E, et al. GARB3 gene deficient mice exhibit impaired social and exploratory behaviours, deficits in non-selective attention and hypoplasia of cebrellar vermal lobules: A potential model of autism spectrum disorder. Behav Brain Res 2008;187(2):207-20
85. Chebib M, Johnston GAR. GABA-activated ligand gated ion channels: medicinal chemistry and molecular biology. J Med Chem 2000;43(8):1427-47
86. Whiting PJ. The GABAA receptor gene family: New opportunities for drug development. Curr Opin Drug Discov Devel 2003;6(5):648-57
87. Sieghart W. GABAA receptors as targets for different classes of drugs. Drugs Future 2006;31(8):685-94
88. Marrosu G, Rachel MG, Biggio G. Paradoxical reactions elicited by diazepam in children with classic autism. Funct Neurol 1987;2(3):355-61
89. Mazzone L, Ruta L. Topiramate in children with autistic spectrum disorders. Brain Dev 2006;28(10):688
90. Fisman S, Steele M. Use of risperidone in pervasive developmental disorders: a case study. J Child Adolesc Psychopharmacol 1996;6(3):177-90
91. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;571:1-31
92. Salgado-Pineda P, Delaveau P, Blin O, Nieoullon A. Dopaminergic contribution to the regulation of emotional perception. Clin Neuropharmacol 2005;28(5):228-37
93. Lauritsen MB, Børglum AD, Betancur C, et al. Investigation of two variants in the DOPA decarboxylase gene in patients with autism. Am J Med Genet 2002;114(4):466-70
94. Anderson GM, Freedman DX, Cohen DJ, et al. Whole blood serotonin in autistic and normal subjects. J Child Psychol Psychiatry 1987;28(6):885-900
95. Corbett R, Hartman H, Kerman LL, et al. effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav 1993;45(1):9-17
96. Takahashi H, Yahata N, Koeda M, et al. Effects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fMRI study. Neuroimage 2005;27(4):991-1001
97. Delaveau P, Salgado-Pineda P, Wicker B, et al. Effect of levodopa on healthy volunteers' facial emotion perception: an fMRI study. Clin Neuropharmacol 2005;28(6):255-61
98. Hariri AR, Mattay VS, Tessitore A, et al. Dextroampheramine modulates the response of the human amygdala. Neuropsychopharmacology 2002;27(6):1036-40
99. Kee KS, Kern RS, Marshall Jr BD, Green Mf. Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. Schizophr Res 1998;31(2-3):159-65
100. Gillberg C. Svennerholm L CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood. Br J Psychiatry 1987;151:89-94
101. Martineau J, Hérault J, Petit E, et al. Catecholaminergic metabolism and autism. Dev Med Child Neurol 1994;36(6):688-97
102. Eto I, Bandy MD, Butterworth CE Jr. Plasma and urinary levels of biopterin, neopterin, and related pterins and plasma levels of folate in infantile autism. J Autism Dev Disord 1992;22(2):295-308
103. Tani Y, Fernell E, Watanabe Y, et al. Decrease in 6R-5,6,7,8-tetrahydrobiopterin content in cerebrospinal fluid of autistic patients. Neurosci Lett 1994;181(1-2):169-72
104. Komori H, Matsuishi T, Yamada S, et al. Cerebrospinal fluid biopterin and biogenic amine metabolites during oral R-THBP therapy for infantile autism. J Autism Dev Disord 1995;25(2):183-93
105. Fernell E, Watanabe Y, Adolfsson I, et al. Possible effects of tetrahydrobiopterin treatment in six children with autism-clinical and positron emission tomography data: a pilot study. Dev Med Child Neurol 1997;39(5):313-8
106. Ernst M, Zametkin AJ, Matochik JA, et al. Low medial prefrontal dopaminergic activity in autistic children. Lancet 1997;350(9078):638
107. Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry 2007;61(4):538-44
108. Posey DJ, Aman MG, Arnold LE, et al. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005;62(11):1266-74
109. Handen BL, Johnson CR. Lubetsky M Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000;30(3):245-55
110. Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 1995;25(3):283-94
111. Niederhofer H, Damodharan SK, Joji R, Corfield A. Atomoxetine treating patients with autistic disorder. Autism 2006;10(6):646-9
112. Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006;45(10):1196-205
113. Carlsson A, Carlsson ML. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin Neurosci 2006;8(1):137-42
114. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004;14(4):251-67
115. Sonesson C, Lin C-H, Hansson L, et al. Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships. J Med Chem 1994;37(17):2735-53
116. Natesan S, Svensson KA, Reckless GE, et al. The dopamine stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther 2006;318(2):818-9
117. Albert VR, Lee MR, Bolden AH, et al. Distinct promoters direct neuronal and nonneuronal expression of rat aromatic L-amino acid decarboxylase. Proc Natl Acad Sci USA 1992;89(24):12053-7
118. Vassilacopoulou D, Sideris DC, Vassiliou AG, Fragoulis EG. Identification and characterization of a novel form of the human L-dopa decarboxylase mRNA. Neurochem Res 2004;29(10):1817-23
119. Chang YT, Mues G, Hyland H. Alternative splicing in the coding region of human aromatic L-amino acid decarboxylase mRNA. Neurosci Lett 1996;202(3):157-60
120. O'Malley KL, Harmon S, Moffat M, et al. The human aromatic L-amino acid decarboxylase gene can be alternatively spliced to generate unique protein isoforms. J Neurochem 1995;65(6):2409-16
121. Ichinose H, Sumi-Ichinose C, Ohye T, et al. Tissue specific alternative splicing of the first exon generates two types of mRNAs in human aromatic L-amino acid decarboxylase. Biochemistry 1992;31(46):11546-50
122. Watanabe Y, Hashimoto S, Kakita A, et al. Neonatal impact of leukemia inhibitory factor on neurobehavioral development in rats. Neurosci Res 2004;48(3):345-53
123. Bejerot S, Nylander L. Low prevalence of smoking in patients with autistic spectrum disorders. Psychiatry Res 2003;119(2):177-82
124. Perry EK, Lee MLW, Martin-Ruiz CM, et al. Cholinergic activity in autism: Abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry 2001;158(7):1058-66
125. Lee M, Martin-Ruiz C, Graham A, et al. Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain 2002;125(7):1483-95
126. Ray MA, Graham AJ, Lee M, et al. Neuronal nicotinic receptor subunits in autism: An immunohistochemical investigation in the thalamus. Neurobiol Dis 2005;19(3):366-77
127. Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adole Psychopharm 2006;16(5):621-9
128. Chez MG, Aimonovitch M, Buchanan T, et al. Treating autistic spectrum disorders in children: Utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol 2004;19(3):165-9
129. Lin N-H, Gunn DE, Ryther KB, et al. Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): An orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. J Med Chem 1997;40(3):385-90
130. Bencherif M, Lovette ME, Fowler KW, et al. RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization. J Pharmacol Exp Ther 1996;279(3):1413-21
131. Lippiello PM, Bencherif M, Gray JA, et al. RJR-2403, A nicotinic agonist with CNS selectivity II. In vivo characterization. J Pharmacol Exp Ther 1996;279(3):1422-9
132. AZD3480 (TC-1734) - Cognitive impairment, including Alzheimer's disease and cognitive dysfunction in schizophrenia. Available from: www.targacept.com/wt/page/tc_1734 [Last accessed 12 May 2008]
133. Cohen C, Bergis OE, Galli F, et al. SSR591813, a novel selective and partial (4(2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther 2003;306(1):407-20